Strong
Steroid-refractory acute GvHD
FDA-approved December 2024 (remestemcel-L). Pivotal trial demonstrated 70% overall response rate at Day 28 in paediatric SR-aGvHD, with four-year survival data.
A Pacific Partnership in Regenerative Health and Manufacturing.
An independent scientific review of mesenchymal stromal cell therapies, contextualised for the Fijian health system and built around an international cGMP supply pathway.
The Opportunity
Why Fiji. Why now.
Non-communicable diseases account for 67.3% of all deaths in Fiji. The probability of premature mortality from NCDs between ages 30 and 70 is 38.8%.
186 / 100k
Diabetes mortality
Age-standardised rate, Fiji
173 / 100k
Ischaemic heart disease
Age-standardised rate, Fiji
78 / 100k
Stroke mortality
Age-standardised rate, Fiji
Source: WHO Fiji Country Profile. Detailed disease-burden analysis in Chapter 2 of the report.
The Scientific Case
The evidence base.
Twelve approved MSC products across seven countries. Over 1,200 registered clinical trials. The report covers 13 indications in depth — these four anchor the strongest case for Pacific health systems.
Moderate
Knee osteoarthritis
67 registered clinical trials. One approved product in the Republic of Korea. Consistent WOMAC pain and function improvements; MRI evidence of cartilage volume preservation.
Moderate
Crohn's perianal fistulae
EMA marketing authorisation granted March 2018 following positive Phase III RCT. Single intralesional injection of allogeneic adipose-derived MSCs achieved significantly higher remission rates.
Emerging · Highest Fiji relevance
Diabetic wounds & chronic ulcers
Robust preclinical evidence. Early clinical case series demonstrate accelerated wound closure in chronic cutaneous ulcerations and diabetic foot ulcers. Directly addresses Fiji's leading NCD burden.
Full evidence tables across all 13 indications appear in Chapter 5 of the report. Every factual claim carries a DOI or PMID citation.
An Expanding Frontier
Longevity, wellness, and frailty.
Beyond reactive disease treatment, MSC therapies are increasingly studied for proactive applications in healthy aging. The clinical evidence base for frailty, age-related inflammation, and wellness indications is expanding rapidly — with particular relevance to populations where ageing intersects with NCD burden.
Frailty Syndrome
Aging frailty
Phase 2 randomised trials of allogeneic MSC infusions in older adults with frailty syndrome have demonstrated improvements in physical performance — including six-minute walk distance and gait speed — and reductions in inflammatory biomarkers. Multiple programs are advancing toward Phase 3.
Inflammaging
Age-related inflammation
"Inflammaging" — chronic low-grade systemic inflammation that accompanies biological aging — is increasingly recognised as a unifying driver of multiple age-related conditions. The immunomodulatory mechanism of MSCs is mechanistically aligned with attenuating this state.
Wellness Medicine
Regenerative wellness
Proactive MSC interventions are increasingly offered globally for quality-of-life, recovery, and performance applications. Evidence quality varies significantly by indication — robust randomised trials remain the standard for any clinical claim, and regulatory diligence is essential.
Longevity and frailty applications are an active extension of the core MSC clinical pipeline. Pacific demographics — where aging populations meet a high NCD burden — represent a particularly compelling deployment context.
The Partnership
How we'll do it.
A clear division of responsibility between Sponsor and Manufacturer. Patient access via established international cGMP supply, not greenfield domestic build-out.
01
PranaGen Bio leads regional access
Clinical strategy, regulatory engagement with the Fiji Medicinal Products Board, the Fiji MRA, and the National Health Research Ethics Review Committee. Patient pathway design and real-world evidence generation.
02
Made Scientific manufactures
cGMP-grade MSC drug product produced under 21 CFR 210/211 and 21 CFR 1271, aligned to ICH Q-series. FDA-registered facility. Independent Quality Unit oversight. International cold-chain logistics.
Learn more about Made's capabilities03
Partnership over local build
International cGMP supply via established US infrastructure delivers patient access years faster than greenfield domestic manufacturing — with progressive technology transfer as the regional ecosystem matures.
Manufacturing & Compliance
U.S. cGMP manufacturing, built to international standards.
Made Scientific is a U.S.-based, FDA-registered cell therapy CDMO (FEI: 3039488058), headquartered in Princeton, NJ. The hUC-WJ-MSC drug product for this partnership is manufactured under a Quality Management System aligned with FDA 21 CFR 1271, 21 CFR 210/211, and ICH Q7, Q9, and Q10 — the international standards that govern modern cell therapy manufacture.
01
Analytics, process control, traceability
Ethically sourced starting cellular material. 2D and 3D expansion protocols with integrated quality control. Every batch is characterised through analytical release testing — identity, purity, potency, sterility — and is consistent, controlled, and traceable from raw material to clinical use.
02
Scale-ready U.S. footprint
Current cleanroom suites at 201 College Road East support clinical-to-commercial supply today. Expanded large-scale ballroom suites at 307 College Road East come online June 2027 — purpose-built to scale with the partnership.
03
Fiji-aligned regulatory pathway
Manufacture aligns with Fiji's Medicinal Products Act 2011 and Classification Scheme Regulations 2021. PranaGen Bioscience holds in-country authorisations — FNHRERC / CHRERC ethics clearance, import permit, listing on the Provisionally Authorized Medicinal Products Register where applicable, and engagement of a Fijian importer licensed by the FCCC.
The Pathway
A staged regional rollout.
-
Phase 112–18 months
Regulatory foundation & partnership formation
Fiji MRA listing for the MSC drug product. FNHRERC ethics approval. Import permit pathway via the Fiji Medicinal Products Board. Sponsor–Manufacturer agreement and quality-system alignment.
-
Phase 218–36 months
Controlled regional access
Initial patient cohorts under a PranaGen Bio-led clinical pathway. International cGMP supply from Made Scientific. Real-world evidence generation aligned to the strongest-evidence indications.
-
Phase 336+ months
Sustained supply & capability transfer
Continued international cGMP supply with progressive regional capability development. Expansion of indications backed by the strongest accumulated evidence and Pacific-specific real-world data.
About
About this review.
This 110-page scientific dossier synthesises the global evidence base for mesenchymal stromal cell (MSC) therapies — across clinical safety, efficacy across 13 indications, regulatory frameworks in eight jurisdictions (EU, Japan, Korea, Australia, India, China, Canada, United States), manufacturing and quality requirements, and the emerging research pipeline.
The review is independent and citation-backed. Every factual claim carries a DOI or PMID reference. Findings are framed at the policy and pathway level to support evidence-based decision-making by health authorities considering whether and how to enable access to MSC-based therapies.
The Report
Fiji MSC Scientific Review 2026 Partnership Edition
Download the reportEditable .docx version available on request.
Get in Touch
Talk to the team.
Talk to PranaGen Bio
Ramon Coronado, M.S., PhD
Chief Executive Officer
rc@cubicbio.com
Talk to Made Scientific
Joe Sinclair
VP, Head of Commercial
joseph.sinclair@madescientific.com